DownloadHi-Res Photo

Giulia Biancon, PhD

Associate Research Scientist

Research & Publications
Biography
News

Research Summary

My research is focused on dissecting the role of splicing factor mutations in myeloid malignancies merging molecular and computational biology.

Coauthors

Selected Publications

Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023)Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.
ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability controlGao Y, Zimmer J, Vasic R, Liu C, Gbyli R, Zheng S, Patel A, Liu W, Qi Z, Li Y, Nelakanti R, Song Y, Biancon G, Xiao A, Slavoff S, Kibbey R, Flavell R, Simon M, Tebaldi T, Li H, Halene S. ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability control. Cell Reports 2023, 42: 113163. PMID: 37742191, PMCID: PMC10636609, DOI: 10.1016/j.celrep.2023.113163.
Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine ProtectionKim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.
3124 – ANALYSIS OF TRANSCRIPTOMIC AND EPITRANSCRIPTOMIC EFFECTS OF THE ACUTE MEGAKARYOBLASTIC LEUKEMIA FUSION PROTEIN RBM15-MKL1Mayday M, Biancon G, Moratti I, Pintado-Urbanc A, Simon M, Tebaldi T, Halene S, Krause D. 3124 – ANALYSIS OF TRANSCRIPTOMIC AND EPITRANSCRIPTOMIC EFFECTS OF THE ACUTE MEGAKARYOBLASTIC LEUKEMIA FUSION PROTEIN RBM15-MKL1. Experimental Hematology 2023, 124: s111. DOI: 10.1016/j.exphem.2023.06.231.
3064 – ALKBH5 MODULATES HEMATOPOIETIC STEM AND PROGENITOR CELL ENERGY METABOLISM THROUGH M6A MODIFICATION-MEDIATED RNA STABILITY CONTROLGao Y, Biancon G, Flavell R, Gbyli R, Halene S, Kibbey R, Li H, Li Y, Liu C, Liu W, Nelakanti R, Patel A, Qi Z, Simon M, Slavoff S, Song Y, Tebaldi T, Vasic R, Xiao A, Zheng S, Zimmer J. 3064 – ALKBH5 MODULATES HEMATOPOIETIC STEM AND PROGENITOR CELL ENERGY METABOLISM THROUGH M6A MODIFICATION-MEDIATED RNA STABILITY CONTROL. Experimental Hematology 2023, 124: s82. DOI: 10.1016/j.exphem.2023.06.171.
Recruited monocytes/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosisÖz H, Cheng E, Di Pietro C, Tebaldi T, Biancon G, Zeiss C, Zhang P, Huang P, Esquibies S, Britto C, Schupp J, Murray T, Halene S, Krause D, Egan M, Bruscia E. Recruited monocytes/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosis. Cell Reports 2022, 41: 111797. PMID: 36516754, PMCID: PMC9833830, DOI: 10.1016/j.celrep.2022.111797.
Deconvolution of in vivo protein-RNA contacts using fractionated eCLIP-seqBiancon G, Busarello E, Joshi P, Lesch B, Halene S, Tebaldi T. Deconvolution of in vivo protein-RNA contacts using fractionated eCLIP-seq. STAR Protocols 2022, 3: 101823. PMID: 36595959, PMCID: PMC9676202, DOI: 10.1016/j.xpro.2022.101823.
Harmonizing the Annotation of Hematopoietic Populations in Single-Cell Atlases with the Cell Marker AccordionBusarello E, Ibnat Z, Biancon G, VanOudenhove J, Lauria F, Viero G, Halene S, Tebaldi T. Harmonizing the Annotation of Hematopoietic Populations in Single-Cell Atlases with the Cell Marker Accordion. Blood 2022, 140: 4968-4969. DOI: 10.1182/blood-2022-162180.
U2AF1 Splicing Factor Mutations Affect RNA Subcellular Compartmentalization in Myeloid MalignanciesBiancon G, Busarello E, Lessard M, Courvan E, Escayola D, VanOudenhove J, Lee V, Krick M, Bewersdorf J, Neugebauer K, Tebaldi T, Halene S. U2AF1 Splicing Factor Mutations Affect RNA Subcellular Compartmentalization in Myeloid Malignancies. Blood 2022, 140: 1271-1272. DOI: 10.1182/blood-2022-170043.
Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction TherapyLiu Y, Browning S, VanOudenhove J, Biancon G, Bar N, Parker T, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Haims A, Wei W, Neparidze N. Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy. Blood 2022, 140: 7086-7087. DOI: 10.1182/blood-2022-168109.
Widespread association of the Argonaute protein AGO2 with meiotic chromatin suggests a distinct nuclear function in mammalian male reproductionGriffin KN, Walters BW, Li H, Wang H, Biancon G, Tebaldi T, Kaya CB, Kanyo J, Lam TT, Cox AL, Halene S, Chung JJ, Lesch BJ. Widespread association of the Argonaute protein AGO2 with meiotic chromatin suggests a distinct nuclear function in mammalian male reproduction. Genome Research 2022, 32: 1655-1668. PMID: 36109149, PMCID: PMC9528986, DOI: 10.1101/gr.276578.122.
Pre-mRNA splicing factor U2AF2 recognizes distinct conformations of nucleotide variants at the center of the pre-mRNA splice site signalGlasser E, Maji D, Biancon G, Puthenpeedikakkal AMK, Cavender CE, Tebaldi T, Jenkins JL, Mathews DH, Halene S, Kielkopf CL. Pre-mRNA splicing factor U2AF2 recognizes distinct conformations of nucleotide variants at the center of the pre-mRNA splice site signal. Nucleic Acids Research 2022, 50: 5299-5312. PMID: 35524551, PMCID: PMC9128377, DOI: 10.1093/nar/gkac287.
Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort StudiesFigueiredo JC, Hirsch FR, Kushi LH, Nembhard WN, Crawford JM, Mantis N, Finster L, Merin NM, Merchant A, Reckamp KL, Melmed GY, Braun J, McGovern D, Parekh S, Corley DA, Zohoori N, Amick BC, Du R, Gregersen PK, Diamond B, Taioli E, Sariol C, Espino A, Weiskopf D, Gifoni A, Brien J, Hanege W, Lipsitch M, Zidar DA, McAlearney A, Wajnberg A, LaBaer J, Lewis E, Binder RA, Moormann AM, Forconi C, Forrester S, Batista J, Schieffelin J, Kim D, Biancon G, VanOudenhove J, Halene S, Fan R, Barouch DH, Alter G, Pinninti S, Boppana SB, Pati SK, Latting M, Karaba AH, Roback J, Sekaly R, Neish A, Brincks AM, Granger DA, Karger AB, Thyagarajan B, Thomas SN, Klein SL, Cox AL, Lucas T, Furr-Holden D, Key K, Jones N, Wrammerr J, Suthar M, Wong S, Bowman NM, Simon V, Richardson LD, McBride R, Krammer F, Rana M, Kennedy J, Boehme K, Forrest C, Granger SW, Heaney CD, Lapinski M, Wallet S, Baric RS, Schifanella L, Lopez M, Fernández S, Kenah E, Panchal AR, Britt WJ, Sanz I, Dhodapkar M, Ahmed R, Bartelt LA, Markmann AJ, Lin JT, Hagan RS, Wolfgang MC, Skarbinski J. Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infectious Diseases 2022, 9: ofac171. PMID: 35765315, PMCID: PMC9129196, DOI: 10.1093/ofid/ofac171.
In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia 2022, 36: 1313-1323. PMID: 35273342, PMCID: PMC9103411, DOI: 10.1038/s41375-022-01536-x.
MYOCARDIAL IMPACT OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) SECRETOMES IN CARDIO-ONCOLOGY PATIENTSKwan J, Vanoudenhove J, Halder S, Biancon G, Jain K, Chakraborty R, Lustberg M, Pusztai L, Campbell S, Zhao H, Halene S, Hwa J. MYOCARDIAL IMPACT OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) SECRETOMES IN CARDIO-ONCOLOGY PATIENTS. Journal Of The American College Of Cardiology 2022, 79: 1912. DOI: 10.1016/s0735-1097(22)02903-5.
Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignanciesBiancon G, Joshi P, Zimmer JT, Hunck T, Gao Y, Lessard MD, Courchaine E, Barentine AES, Machyna M, Botti V, Qin A, Gbyli R, Patel A, Song Y, Kiefer L, Viero G, Neuenkirchen N, Lin H, Bewersdorf J, Simon MD, Neugebauer KM, Tebaldi T, Halene S. Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies. Molecular Cell 2022, 82: 1107-1122.e7. PMID: 35303483, PMCID: PMC8988922, DOI: 10.1016/j.molcel.2022.02.025.
Compromised Host Stem Cell Competitiveness Affords Fanconi Stem Cell Engraftment in C-Kit Mutant Humanized MiceWei L, Song Y, Gbyli R, Sefik E, Biancon G, Gao Y, Philbrick W, Patel A, Tebaldi T, Nalepa G, Kupfer G, Flavell R, Halene S. Compromised Host Stem Cell Competitiveness Affords Fanconi Stem Cell Engraftment in C-Kit Mutant Humanized Mice. Blood 2021, 138: 1119. DOI: 10.1182/blood-2021-153777.
U2AF1 Mutations Enhance Stress Granule Response in Myeloid MalignanciesBiancon G, Joshi P, Zimmer J, Hunck T, Gao Y, Lessard M, Courchaine E, Barentine A, Machyna M, Botti V, Qin A, Gbyli R, Patel A, Song Y, Kiefer L, Viero G, Neuenkirchen N, Lin H, Bewersdorf J, Simon M, Neugebauer K, Tebaldi T, Halene S. U2AF1 Mutations Enhance Stress Granule Response in Myeloid Malignancies. Blood 2021, 138: 321. DOI: 10.1182/blood-2021-149618.
ALKBH5 Modulates Hematopoietic Stem and Progenitor Cell Energy Metabolism through m 6a Modification-Mediated RNA StabilityGao Y, Zimmer J, Vasic R, Liu C, Gbyli R, Zheng S, Patel A, Wei L, Nelakanti R, Song Y, Biancon G, Xiao A, Slavoff S, Simon M, Flavell R, Tebaldi T, Li H, Halene S. ALKBH5 Modulates Hematopoietic Stem and Progenitor Cell Energy Metabolism through m 6a Modification-Mediated RNA Stability. Blood 2021, 138: 298. DOI: 10.1182/blood-2021-146049.
Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 CasesLi P, Biancon G, Patel T, Pan Z, Kothari S, Halene S, Prebet T, Xu ML. Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases. Frontiers In Oncology 2021, 11: 730503. PMID: 34589432, PMCID: PMC8474637, DOI: 10.3389/fonc.2021.730503.
Combined liver–cytokine humanization comes to the rescue of circulating human red blood cellsSong Y, Shan L, Gbyli R, Liu W, Strowig T, Patel A, Fu X, Wang X, Xu ML, Gao Y, Qin A, Bruscia EM, Tebaldi T, Biancon G, Mamillapalli P, Urbonas D, Eynon E, Gonzalez DG, Chen J, Krause DS, Alderman J, Halene S, Flavell RA. Combined liver–cytokine humanization comes to the rescue of circulating human red blood cells. Science 2021, 371: 1019-1025. PMID: 33674488, PMCID: PMC8292008, DOI: 10.1126/science.abe2485.
High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid MalignanciesBiancon G, Joshi P, Hunck T, Zimmer J, Gao Y, Machyna M, Botti V, Qin A, Viero G, Neuenkirchen N, Taylor A, Gbyli R, Patel A, Ardasheva A, Fu X, Lin H, Simon M, Neugebauer K, Tebaldi T, Halene S. High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies. Blood 2020, 136: 3-4. DOI: 10.1182/blood-2020-142854.
Reconstruction of Sickle Cell Disease with Circulating Sickling Red Blood Cells in Novel Humanized Cytokines and Liver Mistrg MiceSong Y, Gbyli R, Shan L, Liu W, Gao Y, Patel A, Fu X, Wang X, Xu M, Qin A, Bruscia E, Tebaldi T, Biancon G, Mamillapalli P, Urbonas D, Gonzales D, Krause D, Alderman J, Flavell R, Halene S. Reconstruction of Sickle Cell Disease with Circulating Sickling Red Blood Cells in Novel Humanized Cytokines and Liver Mistrg Mice. Blood 2020, 136: 29-30. DOI: 10.1182/blood-2020-141603.
m6A Modification Prevents Formation of Endogenous Double-Stranded RNAs and Deleterious Innate Immune Responses during Hematopoietic DevelopmentGao Y, Vasic R, Song Y, Teng R, Liu C, Gbyli R, Biancon G, Nelakanti R, Lobben K, Kudo E, Liu W, Ardasheva A, Fu X, Wang X, Joshi P, Lee V, Dura B, Viero G, Iwasaki A, Fan R, Xiao A, Flavell RA, Li HB, Tebaldi T, Halene S. m6A Modification Prevents Formation of Endogenous Double-Stranded RNAs and Deleterious Innate Immune Responses during Hematopoietic Development. Immunity 2020, 52: 1007-1021.e8. PMID: 32497523, PMCID: PMC7408742, DOI: 10.1016/j.immuni.2020.05.003.
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myelomaZiccheddu B, Biancon G, Bagnoli F, De Philippis C, Maura F, Rustad EH, Dugo M, Devecchi A, De Cecco L, Sensi M, Terragna C, Martello M, Bagratuni T, Kastritis E, Dimopoulos MA, Cavo M, Carniti C, Montefusco V, Corradini P, Bolli N. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Advances 2020, 4: 830-844. PMID: 32126144, PMCID: PMC7065476, DOI: 10.1182/bloodadvances.2019000779.
The Genomic and Transcriptomic Landscape of Double-Refractory Multiple MyelomaZiccheddu B, Biancon G, De Philippis C, Bagnoli F, Maura F, Dugo M, Devecchi A, De Cecco L, Sensi M, Terragna C, Martello M, Bagratuni T, Kastritis E, Dimopoulos M, Cavo M, Carniti C, Montefusco V, Corradini P, Bolli N. The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma. Blood 2019, 134: 3056. DOI: 10.1182/blood-2019-122197.
In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg MiceSong Y, Shan L, Gbyli R, Liu W, Fu X, Wang X, Qin A, Patel A, Gao Y, Tebaldi T, Biancon G, Urbonas D, Alderman J, Halene S, Flavell R. In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice. Blood 2019, 134: 338. DOI: 10.1182/blood-2019-130701.
U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA ComplexBiancon G, Joshi P, Hunck T, Gao Y, Botti V, Qin A, Sadykov M, Wang X, Viero G, Neuenkirchen N, Taylor A, Huang J, Ardasheva A, Fu X, Lin H, Pillai M, Kielkopf C, Neugebauer K, Tebaldi T, Halene S. U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex. Blood 2019, 134: 1230. DOI: 10.1182/blood-2019-130759.
PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH InhibitorsGbyli R, Song Y, Liu W, Gao Y, Chandhok N, Fu X, Wang X, Patel A, Sundaram R, Tebaldi T, Biancon G, Ardasheva A, Qin A, Sadykov M, Mamillapalli P, Flavell R, Prebet T, Bindra R, Halene S. PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors. Blood 2019, 134: 4222. DOI: 10.1182/blood-2019-130814.
Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic FailureGao Y, Vasic R, Song Y, Teng R, Gbyli R, Biancon G, Nelakanti R, Kudo E, Liu W, Ardasheva A, Fu X, Wang X, Joshi P, Dura B, Lee V, Viero G, Iwasaki A, Fan R, Xiao A, Flavell R, Li H, Tebaldi T, Halene S. Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure. Blood 2019, 134: 450. DOI: 10.1182/blood-2019-130442.
Analysis of the genomic and transcriptomic landscape of chemoresistant multiple myelomaZiccheddu B, Biancon G, Dugo M, Devecchi A, De Philippis C, Bagnoli F, Maura F, De Cecco L, Gimondi S, Vendramin A, Terragna C, Martello M, Bagratuni T, Kastritis E, Dimopoulos M, Cavo M, Sensi M, Carniti C, Montefusco V, Corradini P, Bolli N. Analysis of the genomic and transcriptomic landscape of chemoresistant multiple myeloma. Clinical Lymphoma Myeloma & Leukemia 2019, 19: e58-e59. DOI: 10.1016/j.clml.2019.09.091.
Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphomaMagni M, Biancon G, Rizzitano S, Cavanè A, Paolizzi C, Dugo M, Corradini P, Carniti C. Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma. British Journal Of Cancer 2019, 121: 567-577. PMID: 31474759, PMCID: PMC6889385, DOI: 10.1038/s41416-019-0557-8.
From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?Bewersdorf JP, Ardasheva A, Podoltsev NA, Singh A, Biancon G, Halene S, Zeidan AM. From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities? Blood Reviews 2019, 37: 100587. PMID: 31400824, DOI: 10.1016/j.blre.2019.100587.
PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B‐CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIESCarniti C, Biancon G, Banfi S, Vella C, Magni M, Pennisi M, Anna D, Guidetti A, Corradini P. PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B‐CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES. HemaSphere 2019, 3: 599-600. DOI: 10.1097/01.hs9.0000563532.69483.ec.
Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise SpecifiedMaura F, Bolli N, Leongamornlert D, Carniti C, Dodero A, Abascal F, Testi A, Rodriguez-Martin B, Pellegrinelli A, Biancon G, Magni M, Chiappella A, Martincorena I, Tubio J, Pruneri G, Campbell P, Corradini P. Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified. Blood 2018, 132: 4115. DOI: 10.1182/blood-2018-99-112094.
Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA A Pilot StudyBiancon G, Gimondi S, Vendramin A, Carniti C, Corradini P. Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA A Pilot Study. Journal Of Molecular Diagnostics 2018, 20: 859-870. PMID: 30165206, DOI: 10.1016/j.jmoldx.2018.07.006.
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroupsBolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai YT, Mudie L, O’Meara S, Raine K, Teague JW, Butler AP, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson KC, Moreau P, Minvielle S, Campbell PJ, Papaemmanuil E, Avet-Loiseau H, Munshi NC. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia 2018, 32: 2604-2616. PMID: 29789651, PMCID: PMC6092251, DOI: 10.1038/s41375-018-0037-9.
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroupsBolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai Y, Mudie L, O’Meara S, Raine K, Teague J, Butler A, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson K, Moreau P, Minvielle S, Campbell P, Papaemmanuil E, Avet-Loiseau H, Munshi N. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia 2018, 32: 2604-2616. PMCID: PMC6286326, DOI: 10.1038/s41375-018-0037-9.
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroupsBolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai Y, Mudie L, O’Meara S, Raine K, Teague J, Butler A, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson K, Moreau P, Minvielle S, Campbell P, Papaemmanuil E, Avet-Loiseau H, Munshi N. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia 2017, 1-31. DOI: 10.1038/leu.2017.344.
Synergistic Anti-Tumor Efficacy of BET Inhibitors JQ1 and Otx-015 in Combination with Dasatinib in Preclinical Models of T-Cell LymphomasRizzitano S, Cavanè A, Piazzoni M, Vendramin A, Gimondi S, Biancon G, Malan S, Dodero A, Corradini P, Carniti C. Synergistic Anti-Tumor Efficacy of BET Inhibitors JQ1 and Otx-015 in Combination with Dasatinib in Preclinical Models of T-Cell Lymphomas. Blood 2016, 128: 3967. DOI: 10.1182/blood.v128.22.3967.3967.
Disease Monitoring in Multiple Myeloma Patients Using Liquid Biopsy and Next Generation Sequencing of IGH Gene RearrangementsGimondi S, Biancon G, Vendramin A, Zaninelli S, Rizzitano S, Malan S, Bermema A, Montefusco V, Carniti C, Corradini P. Disease Monitoring in Multiple Myeloma Patients Using Liquid Biopsy and Next Generation Sequencing of IGH Gene Rearrangements. Blood 2016, 128: 4430. DOI: 10.1182/blood.v128.22.4430.4430.
Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantationGimondi S, Dugo M, Vendramin A, Bermema A, Biancon G, Cavané A, Corradini P, Carniti C. Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation. Experimental Hematology 2016, 44: 624-634.e1. PMID: 27013207, DOI: 10.1016/j.exphem.2016.03.005.
a Novel Method for the Detection of Minimal Residual Disease in B-Cell Malignancies: Ion Semiconductor Sequencing for the Evaluation of Igh Gene RearrangementsGimondi S, Cavanè A, Vendramin A, Biancon G, Corradini P, Carniti C. a Novel Method for the Detection of Minimal Residual Disease in B-Cell Malignancies: Ion Semiconductor Sequencing for the Evaluation of Igh Gene Rearrangements. Blood 2014, 124: 2983. DOI: 10.1182/blood.v124.21.2983.2983.

Edit Profile

Contact Information

Research & Publications

Biography

News

Research Summary

Coauthors

Selected Publications